Drugs / Drospirenone Ethinyl Estradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT07318337 | Jul 2024 → Jun 2025 | polycystic ovary syndrome | Mst.Sumyara Khatun | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05156879 Comparator | Dec 2021 → Dec 2024 | pelvis syndrome | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drospirenone ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156879 ↗ |
| Known as | Yasmin | “Yasmin(Drospirenone ethinyl estradiol tablet) will be used as positive control.” NCT05156879 ↗ |
| Route | Oral | “oral contraceptive pill containing 3mg drospirenone and either 30 μg EE or 20 μg EE” PMID 26613823 ↗ Nov 2015 |